...drug discovery include its September partnership with Recursion Pharmaceuticals Inc....

...Dravet syndrome into the clinic. Other portfolio companies include synthetic biology companies Senti Biosciences Inc. and Synthego Corp.; Recursion Pharmaceuticals Inc....

...lab, including Hydra Biosciences Inc., Navigen Pharmaceuticals Inc. and Recursion Pharmaceuticals Inc....

...Capital Management and Samsara BioCapital —joined Recursion Pharmaceuticals Inc.’s...
...to do discover rare disease candidates. Lauren Martz Bayer AG Recursion Pharmaceuticals Inc. Pulmonary Pulmonary...

...guidance; its stock fell 12% in after-hours trading. Recursion takes out digital research play Vium Recursion Pharmaceuticals Inc....
...Dihydroorotate dehydrogenase EGFR (ErbB1; HER1) - Epidermal growth factor receptor BioCentury Staff IMU-838 Spravato, esketamine (jnj-54135419) Immunic Inc. Johnson & Johnson Recursion Pharmaceuticals Inc. Vium...

...A/S (CSE:LUN) acquired in October (see “Astellas Becomes CytomX’s First New Partner Since 2017” ). Recursion Pharmaceuticals Inc....
...30. Reali was president and CEO of Clinical Innovations LLC. Robin Sawka, BioCentury Staff Qiagen N.V. CytomX Therapeutics Inc. Recursion Pharmaceuticals Inc. 89bio...

...that trigger immune attack (see "Driving Neoantigen Production via DNA Mismatch Repair" ). AI company Recursion Pharmaceuticals Inc....
...BioCentury Staff National Institute for Health and Care Excellence (NICE) Bristol Myers Squibb Co. NeoPhore Ltd. Medicxi Ventures Leap Therapeutics Inc. Recursion Pharmaceuticals Inc. Achilles...

...drug discovery. That includes a Phase I trial launch for a repurposing candidate found by Recursion Pharmaceuticals Inc.’s...

...with some techniques -- the cells need to be fixed. High throughput single-cell imaging company Recursion Pharmaceuticals Inc....

...deeper into the clinic. Led by Baillie Gifford’s Scottish Mortgage Investment Trust, the round by Recursion Pharmaceuticals Inc....